Bristol-Myers Squibb Company (BMY) : 17 analysts are covering Bristol-Myers Squibb Company (BMY) and their average rating on the stock is 2.65, which is read as a Hold. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 2 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 10 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Bristol-Myers Squibb Company (BMY) : Currently there are 13 street experts covering Bristol-Myers Squibb Company (BMY) stock. The most bullish and bearish price target for the stock is $100 and $48 respectively for the short term. The average price target of all the analysts comes to $69.15. The estimated standard deviation from the target is $13.34.
Shares of Bristol-Myers Squibb Company appreciated by 0.76% during the last five trading days but lost 20.78% on a 4-week basis. Bristol-Myers Squibb Company has dropped 15.52% during the last 3-month period . Year-to-Date the stock performance stands at -12%. Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Tuesday. Though the stock opened at $59.51, the bulls momentum made the stock top out at $60.04 level for the day. The stock recorded a low of $59.3 and closed the trading day at $59.86, in the green by 1.01%. The total traded volume for the day was 10,582,599. The stock had closed at $59.26 in the previous days trading.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.